Bio-Techne Corp.(NASDAQ : TECH)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-1.66%||10.64||0.7%||$743.78m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.67%||201.39||1.9%||$423.27m|
|GILD||Gilead Sciences, Inc.||-0.40%||69.55||1.0%||$408.62m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.27%||593.98||2.7%||$324.29m|
|NTLA||Intellia Therapeutics, Inc.||-1.24%||137.07||2.3%||$190.45m|
|CRSP||CRISPR Therapeutics AG||0.96%||122.59||0.6%||$136.47m|
|EXAS||EXACT Sciences Corp.||1.82%||106.11||18.1%||$130.59m|
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.